Subscribe or Manage Preferences

Both Tofacitinib and Baricitinib in Combination with MTX Are Efficacious in Patients with RA

VBCR - December 2017, Vol 6, No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

This study assessed the comparative effectiveness of the Janus kinase 1/2 inhibitors, tofacitinib and baricitinib, in patients with rheumatoid arthritis (RA) using a network meta-analysis and Cochrane systematic review of randomized controlled trials from 7 electronic databases and 2 trial registries. Included trials compared tofacitinib or baricitinib alone or in combination with methotrexate (MTX) versus placebo, MTX, or other traditional or biologic disease-modifying antirheumatic drugs. The primary outcome assessed in the network meta-analysis was American College of Rheumatology (ACR) 50% improvement criteria (ACR50); secondary outcomes included remission according to the Disease Activity Score (DAS28), functional ability measured by the Health Assessment Questionnaire, and serious adverse events (SAEs).

Of the 21 trials that met the inclusion criteria (n = 9839), 14 evaluated tofacitinib and 7 evaluated baricitinib; 2 of the tofacitinib trials were at high risk for reporting bias; selection and performance bias could not be evaluated in all 7 trials. Compared with placebo, all drug combinations were effective in achieving ACR50 at 12 weeks, including (from most to least effective) baricitinib 8 mg + MTX, tofacitinib 10 mg + MTX, tofacitinib 5 mg + MTX, baricitinib 2 mg + MTX, baricitinib 4 mg + MTX, bari­citinib 4-mg monotherapy, adalimumab + MTX, tofacitinib 10-mg monotherapy, tofacitinib 10-mg monotherapy, MTX, and adalimumab monotherapy. Of these, the most effective combinations were tofacitinib 10 mg + MTX (ACR50, 11.3; 5.9-21.4) and baricitinib 8 mg + MTX (ACR50, 13.5; 5.8-31.3); these 2 combinations were also the most effective compared with MTX (4.6 [3.5, 6.2] and 5.6 [3.1, 10.1], respectively). In terms of the secondary outcome of DAS28, the most effective drugs compared with MTX were (from most to least effective) tofacitinib 10 mg + MTX, adalimumab + MTX, tofacitinib 5 mg + MTX, baricitinib 4 mg + MTX, baricitinib 8 mg + MTX, baricitinib 2 mg + MTX, tofacitinib 10-mg monotherapy, baricitinib 4 mg, tofacitinib 5-mg monotherapy, and placebo. SAEs were less likely to occur in the placebo, tofacitinib 5 mg + MTX, tofacitinib 10 mg + MTX, MTX, baricitinib 8 mg + MTX, adalimumab, tofacitinib 10-mg monotherapy, tofacitinib 5 mg, baricitinib 4 mg + MTX, baricitinib 4 mg, and adalimumab + MTX groups; the class differences for SAEs between tofacitinib and baricitinib were small, and not considered clinically meaningful.

These results showed that tofacitinib 10 mg and baricitinib 8 mg combined with MTX were among the most efficacious options assessed in this study for patients with RA, with similar safety outcomes.

Source: Zamora N, Lopez-Olivo MA, Tayar J, et al. Comparative effectiveness of tofacitinib versus bari­citinib in rheumatoid arthritis using a systematic review and network meta-analysis of randomized trials. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 531.

Related Items
Working in Cold Environment Increases Risk for RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Treatment with Methotrexate Alone Yields Similar Outcomes to Combination Therapy in Early RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Adalimumab Biosimilar Shown to Be Safe and Effective in Patients with RA
Alice Goodman
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
Leslie Wyatt
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Rheumatoid Arthritis
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology